Journal article
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Abstract
BACKGROUND: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies.
METHODS: We performed a post-hoc analysis of the EMPEROR-Reduced …
Authors
Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B
Journal
The Lancet Diabetes & Endocrinology, Vol. 10, No. 1, pp. 35–45
Publisher
Elsevier
Publication Date
January 2022
DOI
10.1016/s2213-8587(21)00292-8
ISSN
2213-8587